Independent · evidence-anchored·Reviewed by the GLPHelper Medical Team
EN·ES
glp·helper
Find a Provider →
glphelper.com/semaglutide/texas/sugar-land
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Sugar Land, TX

Verified Semaglutide providers in Sugar Land, TX. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
29
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Texas
30 of 30 shown

Find a Semaglutide provider in Texas.

Every entry is checked against the NPI registry and the Texas medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Texas city · /semaglutide/texas/{city}
Missouri City
29.56°N
31 →
Rosenberg
29.55°N
19 →
Pearland
29.56°N
37 →
Houston
29.76°N
37 →
Friendswood
29.51°N
28 →
Pasadena
29.65°N
26 →
§ 03Getting Semaglutide in Sugar Land
30 providers · Sugar Land, TX

How to get Semaglutide in Sugar Land.

30 GLP-1 prescribers and 7 local resource types are on record for Sugar Land, plus 3 nearby towns in the directory.

Prescribers in Sugar Land
30 prescribers
30 GLP-1 prescribers in Sugar Land, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (15), Family Medicine (11) and Internal Medicine (2). Any Texas-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are Missouri City (31 providers), Rosenberg (19 providers) and Pearland (37 providers).
Around the prescription in Sugar Land
7 listed nearby
6 dietitians, 2 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Sugar Land.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Sugar Land

Sugar Land, Texas has a population of 111,026 people. The adult obesity rate in Sugar Land is an age-adjusted estimate of 24.2%, 11.4 percentage points below the Texas state rate of 35.6%. Diagnosed diabetes reaches 9.8% of adults in Sugar Land. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 21% of adults in Sugar Land.

of Sugar Land adults have obesity
24.2%
diagnosed diabetes
9.8%
no regular physical activity
21%

Age-adjusted estimates for Sugar Land, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossOzempic babies explained
§ 05Support around Semaglutide in Sugar Land
6 dietitians

The prescription is one part. Here is the rest, in Sugar Land.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Sugar Land, TX, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Nelda Aguirre, M.S.,R.D., L.D
RD
Registered dietitian
13107 Parkbrook Way Ln
Call 281-723-5005NPI 1720338817
Alice Aladume, RDN
RD
Registered dietitian
2002 Holcombe Blvd
Call 713-791-1414NPI 1093566770
Suzanne Alexander, RD
RD
Registered dietitian
1705 Jackson St
Call 281-633-4028NPI 1336368455
Mahbanoo Bastani
RD
Registered dietitian
3954 May Ridge Ln
Call 832-382-5178NPI 1821985060
Laura Boudreaux, MPH, RD, LD
RD
Registered dietitian
14023 Southwest Fwy
Call 281-325-4256NPI 1740573682
Judy Bradicich, RD, CDCES
RD
Registered dietitian
67 Grassy Knls
Call 713-553-6261NPI 1710760384

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Amanda Compton, FNTP, RWP
NUTRITIONIST
Nutritionist
4614 Magnolia Ln
Call 281-881-9025NPI 1720766801
Deborah Lea, MS RD
NUTRITIONIST
Nutritionist · Education
904 Fm 359 Rd
Call 281-704-2830NPI 1952168106
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Texas

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Weight loss doctors in Texas
Board-certified prescribers verified against the NPI registry.
Weight loss clinics in Texas
Clinics running GLP-1 programs, telehealth & in-person.
Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Semaglutide in Alabama→Semaglutide in Alaska→Semaglutide in Arizona→Semaglutide in Arkansas→Semaglutide in California→Semaglutide in Colorado→Semaglutide in Connecticut→Semaglutide in Delaware→Semaglutide in Florida→Semaglutide in Georgia→Semaglutide in Hawaii→Semaglutide in Idaho→Semaglutide in Illinois→Semaglutide in Indiana→Semaglutide in Iowa→Semaglutide in Kansas→Semaglutide in Kentucky→Semaglutide in Louisiana→Semaglutide in Maine→Semaglutide in Maryland→Semaglutide in Massachusetts→Semaglutide in Michigan→Semaglutide in Minnesota→Semaglutide in Mississippi→Semaglutide in Missouri→Semaglutide in Montana→Semaglutide in Nebraska→Semaglutide in Nevada→Semaglutide in New Hampshire→Semaglutide in New Jersey→Semaglutide in New Mexico→Semaglutide in New York→Semaglutide in North Carolina→Semaglutide in North Dakota→Semaglutide in Ohio→Semaglutide in Oklahoma→Semaglutide in Oregon→Semaglutide in Pennsylvania→Semaglutide in Rhode Island→Semaglutide in South Carolina→Semaglutide in South Dakota→Semaglutide in Tennessee→Semaglutide in Texas→Semaglutide in Utah→Semaglutide in Vermont→Semaglutide in Virginia→Semaglutide in Washington→Semaglutide in West Virginia→Semaglutide in Wisconsin→Semaglutide in Wyoming→
Related GLP-1 research
hair shedding during weight loss
Why rapid loss can shed hair, and what helps it regrow.
the GLP-1 timeline to appetite suppression
When appetite changes show up, and when the weight curve usually follows.
do oral GLP-1 pills work
Pills and drops vs injections: what the evidence supports.
§ 09Frequently asked: Semaglutide in Texas

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]